[{"AccountsPayableCurrent_0_Q1_USD":6645000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":9583000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":24708000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":15276000.0,"IncreaseDecreaseInOtherOperatingAssets_1_Q1_USD":99000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-6632000.0,"PaymentsToAcquireProductiveAssets_1_Q1_USD":954000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":333631000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q1_USD":5067000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1_Q1_USD":14900000.0,"OtherPrepaidExpenseCurrent_0_Q1_USD":5491000.0,"IncomeLossFromEquityMethodInvestments_1_Q1_USD":13515000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":367000.0,"RepaymentsOfNotesPayable_1_Q1_USD":235347000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":203000.0,"ProceedsFromIssuanceOfLongTermDebt_1_Q1_USD":380000000.0,"IncreaseDecreaseInInterestPayableNet_1_Q1_USD":664000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-82686000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":6559000.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":-10549000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":60076000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":139915000.0,"IncreaseDecreaseInPrepaidExpensesOther_1_Q1_USD":-1592000.0,"PaymentsOfDebtIssuanceCosts_1_Q1_USD":5065000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q1_USD":6804000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":555000.0,"RestrictedCash_0_Q1_USD":833000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1_Q1_USD":119203000.0,"ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1_Q1_USD":14932000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":64778000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q1_USD":6804000.0,"PaymentsOfLoanCosts_1_Q1_USD":11470000.0,"OtherNoncashIncomeExpense_1_Q1_USD":-9000.0,"OtherDepreciationAndAmortization_1_Q1_USD":2424000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":46106000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":47199000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":7954000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_1_Q1_USD":144000.0,"IncomeTaxesReceivableNoncurrent_0_Q1_USD":3972000.0,"FinanceLeaseRightOfUseAssetAmortization_1_Q1_USD":457000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q1_USD":8511000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":23193000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":274734000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":154233000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q1_USD":433103000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q1_USD":432589000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":41000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":15276000.0,"RestrictedCashNoncurrent_0_Q1_USD":833000.0,"OtherAssetsNoncurrent_0_Q1_USD":1308000.0,"GainsLossesOnExtinguishmentOfDebt_1_Q1_USD":-15464000.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":139915000.0,"NetIncomeLoss_1_Q1_USD":-83053000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-55101000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":68403000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":261432000.0,"LiabilitiesCurrent_0_Q1_USD":98040000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":605409000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":1154000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":147000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-82906000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-1.4,"DueFromRelatedPartiesCurrent_0_Q1_USD":26282000.0,"CommonStockValue_0_Q1_USD":1000.0,"CommonStockSharesOutstanding_0_Q1_shares":63004000.0,"CommonStockSharesIssued_0_Q1_shares":63004000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":332798000.0,"AssetsCurrent_0_Q1_USD":534218000.0,"Assets_0_Q1_USD":605409000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":12711000.0,"AdditionalPaidInCapital_0_Q1_USD":1173204000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":512000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":13905000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":1460000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1331653000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":59463000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":59463000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":203000.0,"ShareBasedCompensation_1_Q1_USD":15276000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":26325000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":66013000.0,"PreferredStockValue_0_Q1_USD":0.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PreferredStockSharesAuthorized_0_Q1_shares":230000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0,"OperatingIncomeLoss_1_Q1_USD":-72476000.0,"OperatingExpenses_1_Q1_USD":92338000.0,"InterestPayableCurrent_0_Q1_USD":6323000.0,"InterestPaidNet_1_Q1_USD":7891000.0,"InterestExpense_1_Q1_USD":9941000.0,"IncomeTaxesPaidNet_1_Q1_USD":-9000.0,"DebtInstrumentInterestRateStatedPercentage_0_Q1_pure":0.05,"ConvertibleLongTermNotesPayable_0_Q1_USD":226158000.0,"CommonStockSharesAuthorized_0_Q1_shares":200000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0,"CommitmentsAndContingencies_0_Q1_USD":null,"StockholdersEquity_0_Q1_USD":-157936000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":19862000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200508"}]